Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Onyx Pharmaceuticals has rejected Amgen’s takeout offer of $120 per share in cash and said it will seek additional bidders. I believe there are five key potential suitors for Onyx, each with a unique motivation to gain control of the company’s most important asset—the blood cancer drug Kyprolis.
Help employers find you! Check out all the jobs and post your resume.
